Alpine Immune Sciences, Inc. (ALPN)
$8.3
Rating:
Recommendation:
Buy
| Symbol | ALPN |
|---|---|
| Price | $8.3 |
| Beta | 1.313 |
| Volume Avg. | 0.12M |
| Market Cap | 381.090M |
| Shares () | - |
| 52 Week Range | 4.82-10.3 |
| 1y Target Est | - |
| DCF Unlevered | ALPN DCF -> | |
|---|---|---|
| DCF Levered | ALPN LDCF -> | |
| ROE | -41.76% | Strong Sell |
| ROA | -18.54% | Sell |
| Operating Margin | - | |
| Debt / Equity | 60.21% | Buy |
| P/E | - | |
| P/B | 1.44 | Strong Buy |
Latest ALPN news
About
Download (Excel)Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.